Menu Philippe 4/A

What Happened

• Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA (SOPH), received equity awards on April 2, 2026: 112,936 RSUs and 164,671 RSUs reported as derivative/contingent rights (total 277,607 RSUs). The awards were granted at $0.00 (no cash paid).
• The Form 4/A amends the April 3, 2026 filing to correct the amount of securities beneficially owned following the transaction; the corrected total ownership is 286,552 ordinary shares (see footnote F2).

Key Details

• Transaction date: April 2, 2026; Grant/award code: A; price reported: $0.00.
• Shares reported acquired: 112,936 (direct RSUs) + 164,671 (derivative RSUs) = 277,607 RSUs.
• Shares beneficially owned following transaction (corrected): 286,552 ordinary shares (per F2).
• Vesting (per footnotes): F1 — each RSU converts to one share, 25% vests April 2, 2027, remaining 75% vest in equal quarterly installments through April 2, 2030. F3 references a related option vesting schedule (25% Apr 2, 2027, then equal monthly installments through Apr 2, 2030).
• Filing status: Amended Form 4/A filed April 8, 2026 to correct the previously reported ownership figure; original Form 4 was filed April 3, 2026.

Context

• These are time-vested RSU awards (contingent on continued service), not open-market purchases or sales — they do not represent an immediate market purchase or sale.
• No cash changed hands for the grant; RSUs typically convert to shares as they vest. This award should be viewed as compensation/retention rather than a direct insider bullish/sell signal.
• The amendment corrects reporting but does not change the nature of the award.